MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer

A. Petrelli, S.E. Bellomo, I. Sarotto, F. Kubatzki, P. Sgandurra, F. Maggiorotto, M.R. Di Virgilio, R. Ponzone, E. Geuna, D. Galizia, A.M. Nuzzo, E. Medico, U. Miglio, E. Berrino, T. Venesio, S. Ribisi, P. Provero, A. Sapino, S. Giordano, F. Montemurro

Research output: Contribution to journalArticlepeer-review


Purpose Overexpression of miR-100 in stem cells derived from basal-like breast cancers causes loss of stemness, induction of luminal breast cancer markers and response to endocrine therapy. We, therefore, explored miR-100 as a novel biomarker in patients with luminal breast cancer. Methods miR-100 expression was studied in 90 patients with oestrogen-receptor-positive/human-epidermal growth factor receptor 2-negative breast cancer enrolled in a prospective study of endocrine therapy given either preoperatively, or for the treatment of de novo metastatic disease. Response was defined as a Ki67 ≤2.7% after 21±3 days of treatment. The prognostic role of miR-100 expression was evaluated in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) and The Cancer Genome Atlas (TCGA) breast cancer datasets. Additionally, we explored the correlation between miR-100 and the expression its targets reported as being associated with endocrine resistance. Finally, we evaluated whether a signature based on miR-100 and its target genes could predict the luminal A molecular subtype. Results Baseline miR-100 was significantly anticorrelated with baseline and post-treatment Ki67 (p
Original languageEnglish
JournalESMO Open
Issue number5
Publication statusPublished - 2020


  • endocrine therapy
  • luminal breast cancer
  • miR-100
  • prognosis
  • response prediction
  • bc p 1 13
  • hepatocyte nuclear factor 3alpha
  • Ki 67 antigen
  • letrozole
  • mammalian target of rapamycin
  • microRNA 100
  • polo like kinase 1
  • somatomedin C receptor
  • tamoxifen
  • adult
  • Article
  • cancer adjuvant therapy
  • cancer hormone therapy
  • cancer patient
  • cancer prognosis
  • cancer resistance
  • cancer surgery
  • cohort analysis
  • controlled clinical trial
  • controlled study
  • drug resistance
  • estrogen receptor positive breast cancer
  • female
  • gene expression level
  • human
  • human cell
  • human epidermal growth factor receptor 2 negative breast cancer
  • human tissue
  • luminal A breast cancer
  • luminal B breast cancer
  • major clinical study
  • overall survival
  • predictive value
  • prospective study
  • short course therapy
  • treatment response


Dive into the research topics of 'MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer'. Together they form a unique fingerprint.

Cite this